The Cairo-Bishop criteria is a clinical calculator used to diagnose laboratory tumor lysis syndrome (TLS) in patients with malignancies. This scoring system is particularly applicable to patients with high-grade lymphomas and acute leukemias, which are at high risk for TLS, but it can be used in any patient with a malignancy who is at risk for this syndrome.

The Cairo-Bishop criteria for laboratory TLS is based on changes in laboratory values from baseline, including hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. The clinical utility of this calculator is to identify patients who are experiencing TLS, a potentially life-threatening complication of cancer treatment characterized by rapid release of intracellular components into the bloodstream. Early identification of TLS allows for prompt initiation of treatment to prevent serious complications such as renal failure, cardiac arrhythmias, seizures, and death.

There are no specific exclusion criteria for the use of the Cairo-Bishop criteria. However, it should be noted that this scoring system is not applicable to patients without malignancies or those who are not at risk for TLS. Additionally, the calculator may not be as accurate in patients with pre-existing electrolyte abnormalities or renal dysfunction, as these conditions can also cause changes in the laboratory values used in

Cairo-Bishop criteria for laboratory tumor lysis syndrome

# Criteria
 A. Uric acid >= 476 umol/L or >= 25% increase from baseline (+1)
B. Serum potassium >= 6 mmol/L or >= 25% increase from baseline (+1)
C. Serum phosphorus >= 2.1 mmol/L in children or >= 1.45 mmol/L in adults or 25% increase from baseline (+1)
D. Serum calcium <= 1.75 mmol/L or >= 25% decrease from baseline (+1)

# Conditions
- score >= 2
- true
- score == 0